Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

Genes whose expression was decreased by 1 mM ouabain by more than 2-fold. by Larisa V. Smolyaninova (3600053)

“…<p>Genes whose expression was decreased by 1 mM ouabain by more than 2-fold.</p>…”

Clinical characteristics of patients in the increased-, stable-, and decreased-RPR groups. by Kazuhiko Ikeuchi (9234268)

Subjects:

Intracellular levels of HSPG core proteins, HS and HPSE are decreased in ER stressed MIN6 cells. by Sarita Dhounchak (10924448)

Met decreases MYH1/2 and p21 expression and increases Myf5 and MyoD levels in myotubes. by Eleonora Maniscalco (14599854)

mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

“…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”

* months from treatment initiation. by Kazuhiko Ikeuchi (9234268)

Subjects:

Association between the slope of the ratio of the post-treatment RPR titer compared to the baseline titer and other characteristics using linear regression analysis. by Kazuhiko Ikeuchi (9234268)

Subjects:

Temporal changes in the RPR titer from before to after treatment. by Kazuhiko Ikeuchi (9234268)

Subjects:

Flow chart of the study procedures. by Kazuhiko Ikeuchi (9234268)

Subjects:

RDV and EIDD2801 EC₅₀ and fold-change in VeroE6-ACE2-TMPRSS2. by Agnieszka M. Szemiel (10196243)

Decreased trigger factor association and increased DnaK association with ribosomes furthers protein homeostasis during Mg²⁺ starvation. by Carissa Chan (18310140)

Subjects:

Clustering of metastable states using the first 50 ns of post-translational folding trajectories of CAT-III with ligand bound. by Yang Jiang (46459)

Subjects:

Adjustment for the individual conus medullaris (CM) length (60, 50, 40, and 30 mm for the displayed cases). by Silvan Büeler (18389510)

<i>Wfs1</i> deficiency decreases sleep by altering the activity of Dop2R neurons. by Huanfeng Hao (16484819)

Ce6 decreases the amount of TMV PQS5 upon photo-irradiation. by Congbao Xie (17599247)

Distribution of miRs with a greater than two fold-change. by Stephanie L. Samani (17896610)

Subjects:

LOH resulting in 189R/R produces a strong decrease in drug susceptibility. by Pétra Vande Zande (17628246)

Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

“…<p>Cell lysates were obtained from THP-1 monocytes exposed to reagents as indicated: Lane 1, vehicle; Lane 2, PARP inhibitor olaparib (5 mM, 24 hr); Lane 3, oxLDL (100 mg/mL, 24 hr) or Lane 4, combination of oxLDL and olaparib. …”

GSK343 treatment decreased <i>in vivo</i> tumor volume and growth. by Laura V. Bownes (10276762)

“…(A) Animals treated with GSK343 had significantly decreased fold change in tumor volumes compared to mice treated with vehicle. …”